Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
000-30929
(Commission
File Number)
|
13-4087132
(IRS
Employer Identification No.)
|
£
|
Written
communications pursuant to Rule 425 under the Securities
Act.
|
£
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act.
|
£
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
|
£
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
|
Exhibit
|
|
Number
|
Description
|
Exhibit
No.
|
Description
|
1.1*
|
Form
of Securities Purchase Agreement, dated as of March 24, 2006, by
and among
the Company and the purchasers indicated therein.
|
5.1*
|
Opinion
of Alston & Bird LLP, as counsel to the Company, regarding the
legality of the Shares.
|
23.3*
|
Consent
of Alston & Bird LLP, as counsel to the Company (included in Exhibit
5.1).
|
99.1*
|
Other
Expenses of Issuance and Distribution (as required by Item 14 of
Form
S-3).
|
99.2
|
Press
Release dated March 27, 2006
|
|
||
*
|
Exhibit
number corresponds to the exhibit list contained in the Registration
Statement.
|
Keryx Biopharmaceuticals, Inc. | ||
|
(Registrant) |
|
Date: March 29, 2006 | By: | /s/ Ronald C. Renaud, Jr. |
Ronald
C. Renaud, Jr.
|
||
Senior
Vice President and
|
||
Chief
Financial Officer
|
Exhibit
|
|
Number
|
Description
|
Exhibit
No.
|
Description
|
1.1*
|
Form
of Securities Purchase Agreement, dated as of March 24, 2006, by
and among
the Company and the purchasers indicated therein.
|
5.1*
|
Opinion
of Alston & Bird LLP, as counsel to the Company, regarding the
legality of the Shares.
|
23.3*
|
Consent
of Alston & Bird LLP, as counsel to the Company (included in Exhibit
5.1).
|
99.1*
|
Other
Expenses of Issuance and Distribution (as required by Item 14 of
Form
S-3).
|
99.2
|
Press
Release dated March 27, 2006
|
|
||
*
|
Exhibit
number corresponds to the exhibit list contained in the Registration
Statement.
|